Company intelligence / Profile preview
Biokin Pharmaceutical
Chengdu, Sichuan, Chinaen.baili-pharm.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Biokin has a robust pipeline of innovative oncology drugs with multiple ADCs and multi-specific antibodies in clinical development. Its lead program BL-B01D1/izalontamab brengitecan—a bispecific EGFR x HER3 ADC—has reached Phase 3 for NSCLC and breast cancer. The company has entered a major global partnership with Bristol Myers Squibb for this asset ($800M upfront). Several other ADCs are in early-phase trials targeting HER2+, CD33+, Claudin18.2+ cancers as well as solid tumors[6][8][9].
- Therapeutic areas
- OncologyPulmonology
- Modalities
- Antibody-drug conjugateMonoclonal antibodyBispecific monoclonal antibodyTetraspecific antibodySmall molecule
- Industry
- Biotech
02
Drug pipeline
19 assets18 more assets in the full pipeline.
Request access →03
Partnerships
Bristol Myers Squibb ($800M upfront + milestones/licensing for BL-B01D1)Academic collaborations via Chinese Pediatric Medicine R&D Alliance
Beyond the preview
Go deeper on Biokin Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biokin Pharmaceutical.